Those are definitely fair arguments that could play a huge role if oliceridine doesn't clearly differentiate itself from morphine in both of these trials — and underscore why investors may want to keep any position on the small side for the time being. (fool.com)
So while it's probably unwise to back up the truck with this speculative biotech stock, I do think it's worth owning a small position in case oliceridine hits pay dirt next year. (fool.com)
Now, the first thing to understand about oliceridine's ongoing studies is that the primary endpoint for both trials is the drug's ability to outperform placebo as a pain reliever — a feat it has performed in spades in its mid-stage trials that even led to a breakthrough therapy designation from the FDA last February. (fool.com)